Lynparza (olaparib) vs Kadcyla (trastuzumab emtansine)
Lynparza (olaparib) vs Kadcyla (trastuzumab emtansine)
Lynparza (olaparib) is a targeted therapy known as a PARP inhibitor, used primarily for the treatment of certain types of breast, ovarian, fallopian tube, or peritoneal cancers in patients with specific genetic mutations (BRCA1 or BRCA2). Kadcyla (trastuzumab emtansine) is an antibody-drug conjugate that combines the HER2-targeted properties of trastuzumab with the chemotherapy agent DM1; it is used to treat HER2-positive breast cancer that has spread to other parts of the body or has not responded to previous treatment with other HER2-targeted drugs. The choice between Lynparza and Kadcyla would depend on the patient's specific cancer type, genetic makeup, HER2 status, previous treatments, and overall health, making it essential to consult with an oncologist to determine the most appropriate treatment option.
Difference between Lynparza and Kadcyla
Metric | Lynparza (olaparib) | Kadcyla (trastuzumab emtansine) |
---|---|---|
Generic name | Olaparib | Trastuzumab emtansine |
Indications | Ovarian, breast, pancreatic, and prostate cancer | HER2-positive breast cancer |
Mechanism of action | Poly (ADP-ribose) polymerase inhibitor | Antibody-drug conjugate targeting HER2 receptors |
Brand names | Lynparza | Kadcyla |
Administrative route | Oral | Intravenous |
Side effects | Anemia, nausea, fatigue, vomiting | Fatigue, nausea, musculoskeletal pain, hemorrhage |
Contraindications | Hypersensitivity to olaparib | Hypersensitivity to trastuzumab emtansine or its excipients |
Drug class | PARP inhibitor | Antibody-drug conjugate |
Manufacturer | AstraZeneca and Merck & Co. | Genentech (Roche) |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza, also known by its generic name olaparib, is a targeted therapy drug that has shown efficacy in the treatment of certain types of breast cancer. Specifically, it is a PARP inhibitor that has been approved for use in patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation. Clinical trials have demonstrated that Lynparza significantly improves progression-free survival in these patients compared to standard chemotherapy. Patients with BRCA mutations are more likely to respond to PARP inhibitors because their cancer cells rely on the PARP enzyme to repair their DNA and continue growing.
Studies have shown that Lynparza is particularly effective in delaying disease progression. The OlympiAD study, a phase III clinical trial, compared Lynparza to chemotherapy in patients with BRCA-mutated, HER2-negative metastatic breast cancer. The results indicated that Lynparza reduced the risk of disease progression or death by 42% compared to those who received chemotherapy. Moreover, the median progression-free survival was significantly longer for patients treated with Lynparza, highlighting its potential as a beneficial treatment option for this patient population.
Kadcyla (Trastuzumab Emtansine) Efficacy in Breast Cancer
Kadcyla, known generically as trastuzumab emtansine, is an antibody-drug conjugate that combines the HER2-targeting properties of trastuzumab with the cytotoxic agent DM1. Kadcyla is approved for the treatment of HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane, separately or in combination. Clinical trials have shown that Kadcyla significantly extends both progression-free and overall survival in patients with HER2-positive metastatic breast cancer compared to lapatinib plus capecitabine, a standard treatment regimen.
The EMILIA study, a pivotal phase III clinical trial, demonstrated the efficacy of Kadcyla in patients with previously treated HER2-positive advanced breast cancer. The trial showed that Kadcyla significantly improved median progression-free survival compared to the control group. Additionally, Kadcyla also provided a significant improvement in overall survival. These results support the use of Kadcyla as an effective treatment for patients with advanced HER2-positive breast cancer who have previously received other HER2-targeted therapies and chemotherapy.
Regulatory Agency Approvals
Lynparza
Kadcyla
Access Lynparza or Kadcyla today
If Lynparza or Kadcyla are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us